Carregant...
Toxicity of Cancer Therapy: What the Cardiologist Needs to Know about Angiogenesis Inhibitors
Clinical outcomes for patients with a wide range of malignancies have improved substantially over the last two decades. Tyrosine kinase inhibitors (TKI) are potent signalling cascade inhibitors and have been responsible for significant advances in cancer therapy. By inhibiting vascular endothelial g...
Guardat en:
| Publicat a: | Heart |
|---|---|
| Autors principals: | , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6268130/ https://ncbi.nlm.nih.gov/pubmed/30228246 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/heartjnl-2018-313726 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|